Advertisement
Canada markets close in 3 hours 12 minutes

  • S&P/TSX

    21,789.66
    +81.22 (+0.37%)
     

  • S&P 500

    4,974.76
    -36.36 (-0.73%)
     

  • DOW

    37,880.87
    +105.49 (+0.28%)
     

  • CAD/USD

    0.7272
    +0.0008 (+0.11%)
     

  • CRUDE OIL

    82.94
    +0.21 (+0.25%)
     

  • Bitcoin CAD

    88,083.65
    +663.73 (+0.76%)
     

  • CMC Crypto 200

    1,373.76
    +61.14 (+4.67%)
     

  • GOLD FUTURES

    2,409.40
    +11.40 (+0.48%)
     

  • RUSSELL 2000

    1,938.38
    -4.58 (-0.24%)
     

  • 10-Yr Bond

    4.6100
    -0.0370 (-0.80%)
     

  • NASDAQ

    15,342.34
    -259.16 (-1.66%)
     

  • VOLATILITY

    19.12
    +1.12 (+6.22%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Haemonetics (HAE): Strong Industry, Solid Earnings Estimate Revisions

Zacks Equity Research

One stock that might be an intriguing choice for investors right now is Haemonetics Corporation HAE. This is because this security in the Medical - Products space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Products space as it currently has a Zacks Industry Rank of 60 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Haemonetics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Haemonetics Corporation Price and Consensus

Haemonetics Corporation Price and Consensus
Haemonetics Corporation Price and Consensus

Haemonetics Corporation price-consensus-chart | Haemonetics Corporation Quote

ADVERTISEMENT

In fact, over the past month, current quarter estimates have risen from 74 cents per share to 75 cents per share, while current year estimates have risen from $3.16 per share to $3.35 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Haemonetics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Haemonetics Corporation (HAE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.